What did @kekes.plot actually say?
She described her first month on a GLP-1 medication as mostly side-effect-free, with two main complaints: fatigue and mild nausea concentrated on injection day. She also noted reduced appetite and offered a reasonable explanation, suggesting that eating less means fewer calories to fuel your body, which could explain the tiredness. She was transparent that she is new to this and asked her audience to warn her about what might be coming. That honesty is actually refreshing compared to most transformation content on this platform.
She also plugged FreyaMeds.com as where she obtained her prescription online. That mention is worth noting because it functions as an informal referral, even if she did not use explicit affiliate language. Viewers should understand that telehealth platforms vary widely in how they vet patients and what they prescribe.
Does the science back this up?
Mostly, yes. The side-effect profile she described is consistent with what clinical trials have documented, though she is likely underreporting because one month at a starting dose is the easiest part of this medication journey.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that nausea affected roughly 44% of participants on semaglutide 2.4 mg, with the highest rates during dose escalation. Fatigue is also documented, though less commonly reported as the primary complaint. Her framing of injection-day fatigue as a scheduling issue rather than a warning sign is reasonable at low doses, but it glosses over the fact that side effects typically intensify as doses increase over the following months.
Her calorie-deficit-causes-fatigue hypothesis is physiologically plausible. Research on very low calorie intake consistently links reduced energy availability to fatigue, though GLP-1 medications also have direct central nervous system effects that may contribute independently of food intake.
What did they get wrong (or right)?
She got the basics right. Nausea and fatigue on injection day are real, well-documented, and her strategy of injecting on Sundays to recover before the week starts is actually a practical tip that some clinicians suggest.
What she understated is significant, though. One month in, most patients are on the lowest titration dose. The SUSTAIN and STEP trial data show that gastrointestinal side effects peak during dose escalation, not at baseline. Vomiting, diarrhea, constipation, and acid reflux are all common as doses increase. Saying "I really haven't had that many side effects" after four weeks at a starter dose is a bit like saying a highway is quiet after driving one exit ramp.
She also did not mention the rarer but serious risks that prescribers are required to disclose: pancreatitis, gallbladder disease, and the FDA boxed warning about thyroid C-cell tumors seen in rodent studies (though human relevance remains under study). These are low-probability events, but a 170K-view video that functions as soft advocacy for GLP-1 use probably owes its audience more than a pointer to a third-party website.
What should you actually know?
GLP-1 receptor agonists have a strong evidence base for weight loss, but their side-effect profile is front-loaded in a specific way: it gets harder before it gets easier for many patients. The first month is not representative.
A 2022 analysis by Drucker (Cell Metabolism) noted that GLP-1 receptor agonist tolerability is closely tied to how slowly doses are escalated. Patients who rush titration report significantly more GI distress. Anyone starting one of these medications should have a clear escalation schedule from a licensed prescriber, not just a starting dose.
The appetite suppression she describes is the intended mechanism, but reduced intake also carries real nutritional risks. Research on patients using GLP-1 medications for weight loss has flagged inadequate protein intake and muscle mass loss as concerns, particularly without dietary guidance. Feeling less hungry is not the same as eating optimally.
If you are considering a GLP-1 medication through a telehealth platform, the quality of clinical oversight matters as much as the drug itself. Ask whether you will have ongoing monitoring, not just a prescription.